Philogen (PHIL) Q2 2026 earnings summary

Executive summary

• Total revenue for the period ended June 30, 2026, was €4.26 million, down 51.2% year-over-year, mainly due to lower customer contract revenue and grants.

• Operating expenses increased 12.3% year-over-year to €25.37 million, driven by higher personnel and raw material costs.

• Net loss for the period was €19.59 million, compared to a €14.89 million loss in the prior year.

Financial highlights

• Revenue from customer contracts fell 62.7% year-over-year to €2.05 million.

• Other income, mainly from grants, decreased 31.5% to €2.21 million.

• EBITDA was negative €21.11 million, a 52.2% deeper loss year-over-year.

• EBIT was negative €23.32 million, down 47.3% from the prior year.

• Net financial position remained positive at €325.7 million as of June 30, 2026, but declined from €368.3 million at year-end 2025.

Outlook and guidance

• A new marketing authorization application for Nidlegy™ was submitted to the EMA in July 2026, supported by updated clinical data.

• Multiple late-stage clinical trials are ongoing or planned for Nidlegy™ (melanoma, NMSC), Fibromun (STS, glioblastoma), and OncoFAP platforms.

• Preparatory activities for new clinical trials and regulatory submissions are underway, with several readouts expected in late 2026 and 2027.